2023 could be a big year for the obesity market: from an expected resupply of Novo Nordisk’s blockbuster-in-waiting Wegovy to the med’s key cardiovascular outcomes trial readout and data from Eli Lilly’s potential rival tirzepatide. (Creative Commons CC0)

After a complicated 2022, the new year offers a course correction for the obesity market. We'll hear from Fierce's Fraiser Kansteiner and Querida Anderson on the numerous opportunities ahead in the obesity market. 

Also on the show, Fierce's Kevin Dunleavy and Eric Sagonowsky reflect on the the 37 new drugs approved in 2022. Plus, this week's headlines. 

To learn more about topics in this episode:

• 2023 forecast: With Novo's Wegovy on a supply rebound, 2023 offers course correction and obesity showdown with Lilly

• Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light

• Lilly's tirzepatide slides into FDA fast lane for obesity, turning up heat on Novo Nordisk's Wegovy

• 2022 drug approvals: After Aduhelm fiasco, FDA endorsements drop to 37

• Time to shine, biosims: Amgen's Amjevita readies long-awaited assault on AbbVie's Humira

• Amgen's Humira biosimilar Amjevita hits the market with 2 different list prices

• In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion

• Pfizer warns Comirnaty sales will plummet by nearly two-thirds in 2023. And Paxlovid won't fare much better

• Philips cuts another 6,000 jobs as CPAP recall, supply chain snags send 2022 sales down 3%

• Researchers predict Alzheimer's progression 3.5 years early with unique blood test

The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.